

# MANUFACTURING MEDICINES IN AUSTRALIA: EXAMINING THE NEED FOR INCREASED DOMESTIC CAPABILITY

26 May 2020 | Australia

Legal Briefings - By **Shaun McVicar** and **Emma Iles**

---

There has been much discussion about the need for Australia to increase “sovereign capability” in domestic pharmaceutical manufacturing.



Against an international backdrop this article discusses the identified supply chain risks and considers whether such an initiative is commercially feasible in the absence of significant government investment and intervention. It also looks at two key initiatives already in place designed to help mitigate the risk of medicine supply chain shortages.



## KEY CONTACTS

If you have any questions, or would like to know how this might affect your business, phone, or email these key contacts.



**SHAUN MCVICAR**  
PARTNER,  
MELBOURNE  
+61 3 9288 1587  
Shaun.McVicar@hsf.com



**EMMA ILES**  
PARTNER,  
MELBOURNE  
+61 3 9288 1625  
emma.iles@hsf.com

---

## LEGAL NOTICE

The contents of this publication are for reference purposes only and may not be current as at the date of accessing this publication. They do not constitute legal advice and should not be relied upon as such. Specific legal advice about your specific circumstances should always be sought separately before taking any action based on this publication.

© Herbert Smith Freehills 2023

---

**SUBSCRIBE TO STAY UP-TO-DATE WITH INSIGHTS, LEGAL UPDATES, EVENTS, AND MORE**

Close